Low-dose radiation therapy for osteoarthritis has a well-documented tolerability profile. The German Society for Radiation Oncology (DEGRO) S2e guideline describes it as producing symptomatic pain relief in 60 to 90 percent of patients with almost no acute side effects. The U.S. series by Koneru and colleagues reported no acute grade 2 or higher toxicity.
Each LDRT session is brief — typically 5 to 15 minutes of actual treatment time — and completely painless. The radiation beam itself produces no sensation. Patients lie still while the machine delivers the dose, then leave immediately. No sedation, no recovery time, no restrictions on eating or drinking. Most patients drive themselves to and from appointments.
Radiation-induced skin reactions require cumulative doses in the range of 15 to 20 Gy to develop. LDRT for osteoarthritis uses 3 Gy total — less than one-fifth of that threshold. Transient mild skin sensitivity is possible in theory but has not been commonly reported in the literature at these doses. If any skin reaction occurs, it would be expected to be minor and self-resolving.
Some patients experience a temporary increase in joint pain in the days following their first one or two treatment sessions. This pain flare, if it occurs, is typically short-lived — resolving within days — and does not predict treatment failure. It likely reflects the initial inflammatory response to radiation before the anti-inflammatory and analgesic effects develop. Most patients who experience a flare go on to have a positive treatment response. Setting this expectation beforehand is important.
Response is not immediate. Unlike a corticosteroid injection, which may produce relief within days, the analgesic effects of LDRT develop over weeks to months, not hours. The biological mechanisms — modulation of local inflammatory mediators, reduction in pain receptor sensitivity, microenvironment changes — unfold gradually after treatment ends. Patients completing their final session may notice modest early improvement but should not expect the full response to be apparent at that point.
Published trial endpoints confirm this timeline. The Koneru U.S. series (2025) measured continued improvement at 10 weeks post-treatment compared to end-of-treatment assessment. The Fazilat-Panah double-blind sham-controlled randomized trial (2025) showed statistically significant benefit sustained from month 1 through 6 months. The LoRD-KNeA randomized sham-controlled trial used a 4-month primary endpoint, chosen specifically because response continues developing after treatment ends. Most patients who respond do so over 4 to 12 weeks following treatment completion. A 3-month follow-up is typically used to assess whether a clinically meaningful response has occurred. Not feeling better immediately after the final session does not mean the treatment has not worked.
In the Koneru U.S. series, approximately one-third of treated joints received a second course of LDRT. These retreatments produced additional benefit with no increase in toxicity compared to the initial course. This is a concrete and reassuring finding: the treatment can be repeated if the initial response is partial or if symptoms return over time. The DEGRO guideline also addresses retreatment as an established part of clinical practice in European centers. Standard practice involves a waiting period — often 6 to 12 months — before a second course is considered, to allow full assessment of the first-course response.
Most patients who respond to LDRT experience meaningful relief over months to years. The Fazilat-Panah trial showed significant benefit through 6 months. Large European retrospective series report sustained benefit at 3-month, 6-month, and 12-month follow-up in the majority of responders. Response is not universal — roughly 10 to 40 percent of patients do not have a clinically meaningful response — and relief in responders is not necessarily permanent. Osteoarthritis is a progressive disease; LDRT treats pain and inflammation but does not reverse the underlying joint degeneration. Some patients eventually need retreatment; a minority proceed to joint replacement.
Related pages: Am I a candidate? | Radiation safety and cancer risk | Find an LDRT provider
Medically reviewed by: Robert Warren Floyd, M.D., Ph.D. — Resident Physician, Radiation Oncology, The University of Texas MD Anderson Cancer Center. Last reviewed: August 2, 2026. Independent personal project — not affiliated with or endorsed by MD Anderson Cancer Center. Funding & independence disclosure.